Your browser doesn't support javascript.
loading
The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.
Constantin, Theodora A; Varela-Carver, Anabel; Greenland, Kyle K; de Almeida, Gilberto Serrano; Olden, Ellen; Penfold, Lucy; Ang, Simon; Ormrod, Alice; Leach, Damien A; Lai, Chun-Fui; Ainscow, Edward K; Bahl, Ash K; Carling, David; Fuchter, Matthew J; Ali, Simak; Bevan, Charlotte L.
Afiliação
  • Constantin TA; Imperial Centre for Translational and Experimental Medicine, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK.
  • Varela-Carver A; Imperial Centre for Translational and Experimental Medicine, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK.
  • Greenland KK; Imperial Centre for Translational and Experimental Medicine, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK.
  • de Almeida GS; Imperial Centre for Translational and Experimental Medicine, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK.
  • Olden E; Imperial Centre for Translational and Experimental Medicine, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK.
  • Penfold L; MRC London Institute of Medical Sciences, Imperial College London, Hammersmith Hospital, London, UK.
  • Ang S; Imperial Centre for Translational and Experimental Medicine, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK.
  • Ormrod A; Imperial Centre for Translational and Experimental Medicine, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK.
  • Leach DA; Imperial Centre for Translational and Experimental Medicine, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK.
  • Lai CF; Imperial Centre for Translational and Experimental Medicine, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK.
  • Ainscow EK; Carrick Therapeutics, Nova UCD, Bellfield Innovation Park, Dublin, 4, Ireland.
  • Bahl AK; Carrick Therapeutics, Nova UCD, Bellfield Innovation Park, Dublin, 4, Ireland.
  • Carling D; MRC London Institute of Medical Sciences, Imperial College London, Hammersmith Hospital, London, UK.
  • Fuchter MJ; Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, White City Campus, London, UK.
  • Ali S; Imperial Centre for Translational and Experimental Medicine, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK.
  • Bevan CL; Imperial Centre for Translational and Experimental Medicine, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK. charlotte.bevan@imperial.ac.uk.
Br J Cancer ; 128(12): 2326-2337, 2023 06.
Article em En | MEDLINE | ID: mdl-37076563
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias de Próstata Resistentes à Castração Limite: Humans / Male Idioma: En Revista: Br J Cancer Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias de Próstata Resistentes à Castração Limite: Humans / Male Idioma: En Revista: Br J Cancer Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido